The relationship between serum endocan levels with the presence of contrast-induced nephropathy in patients undergoing coronary angiography

Year 2020, , 393 - 399, 30.12.2020

Gamze Aslan , Onur Baydar

https://doi.org/10.18663/tjcl.720147

Abstract

Aim:Contrast-induced nephropathy (CIN) is associated high mortality and morbidity risks in the patients undergoing coronary angiography (CAG).Endocan, a new endothelial dysfunction biomarker, could be a potential immunoinflammatory biomarker for CIN.We investigated the possible association between serum endocan levels and CIN in the patients undergoing CAG.
Material and Methods:We prospectively enrolled 92 patients undergoing CAG.For each patient, serum endocan levels were assessed at hospital admission before CAG.Contrast-induced nephropathy was defined as an increase in serum creatinine 25% or 0.5 mg/dl from baseline in the first 48 - 72 hours.
Results:Overall, 32 cases (34.8%) of CIN were diagnosed.There were no significant differences between the two groups (CIN and without-CIN) in demographic data and general risk factors. 38 patients (41%) were performed percutaneous coronary intervention. Patients with CIN had higher serum endocan levels (3.68 ng/dl;IQR, 0.78-17.3 vs 1.81 ng/dl;IQR, 0.19-17.4, p:0,002) than patients without CIN. Additionaly; basal glomerular filtration rate, contrast volume, serum endocan level and left ventricle ejection fraction were detected as independent risk factors of CIN (p= 0.014, B:0.94, CI: 0.89-0.98, p= 0.024, B:2.55, CI:1.13-5.77, p= 0.026, B:2.45, CI:1.11-5.42, p= 0.044, B:0.91, CI:0.83-1.43, respectively).
Conclusion:In patients undergoing CAG, high serum endocan levels could be associated with an increased risk for CIN.

Keywords

endocan, contrast-induced nephropathy, endothelial dysfunction

Koroner anjiyografi uygulanan hastalarda serum endokan düzeyleri ile kontrast kaynaklı nefropati varlığı arasındaki ilişki

Abstract

Amaç: Kontrast kaynaklı nefropati (KİN), koroner anjiyografi (KAG) uygulanan hastalarda yüksek mortalite ve morbidite ile ilişkilidir. Yeni bir endotelyal disfonksiyon biyomarkeri olan Endocan, KİN için potansiyel bir immünoenflamatuar biyobelirteç olabilir. KAG uygulanan hastalarda, serum endokan düzeyleri ile KİN arasındaki olası ilişkinin araştırılması amaçlandı.
Gereç ve Yöntemler: KAG yapılan 92 hasta çalışmaya alındı. KAG öncesinde, hastane başvurusunda her hastanın serum endokan düzeyleri değerlendirildi. Kontrast kaynaklı nefropati, maruziyetten 48-72 saat sonrasındaki kreatinin düzeyinin başlangıç serum kreatinin düzeyine göre % 25 veya 0.5 mg / dl artış olması olarak tanımlandı.
Bulgular: Toplam 32 hastada (%34.8) KİN saptandı. KİN olan ve olmayan 2 grup arasında demografik veriler ve genel risk faktörleri açısından anlamlı fark saptanmadı.38 hastaya (%41) perkutanöz koroner girişim yapıldı. KİN saptanan hastalarda serum endokan düzeyleri (3.68 ng/dl;IQR, 0.78-17.3 karşı 1.81 ng/dl;IQR, 0.19-17.4, p: 0,002) KİN olmayan hastalara göre daha yüksek bulundu. Ek olarak; bazal glomerüler filtrasyon hızı, kontrast volümü, serum endokan ve sol ventrikül ejeksiyon fraksiyonu KİN için bağımsız risk faktörü olarak saptandı (p= 0.014, B: 0.94, CI: 0.89-0.98, p= 0.024, B: 2.55, CI: 1.13-5.77, p= 0.026, B: 2.45, CI: 1.11-5.42, p= 0.044, B: 0.91, CI: 0.83-1.43, sırasıyla).
Sonuç: KAG yapılan hastalarda, yüksek serum endokan seviyeleri KİN oluşma riski ile ilişkili olabilir.

Keywords

endokan, kontrast ilişkili nefropati, endotelyal disfonksiyon

References

• 1. Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, Marana I, Grazi M, Veglia F, Bartorelli AL. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. Journal of the American College of Cardiology 2004; 44: 1780-5.
• 2. Nakamura T, Ako J, Kadowaki T, Funayama H, Sugawara Y, Kubo N, Momomura S. Impact of acute hyperglycemia during primary stent implantation in patients with ST-elevation myocardial infarction. Journal of Cardiology 2009; 53: 272-7.
• 3. Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, Devos R, Tonnel AB. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. The Journal of Biological Chemistry 1996; 271: 20458-64.
• 4. Bechard D, Scherpereel A, Hammad H et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. Journal of Immunology 2001; 167: 3099-106.
• 5. Lee YH, Kim SY, Moon H et al. Endocan as a marker of microvascular inflammation in kidney transplant recipients. Scientific Reports 2019; 9: 1854.
• 6. Zhao T, Kecheng Y, Zhao X, Hu X, Zhu J, Wang Y, Ni J. The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease: A meta-analysis. Medicine 2018; 97: 13407.
• 7. Wang XS, Yang W, Luo T, Wang JM, Jing YY. Serum endocan levels are correlated with the presence and severity of coronary artery disease in patients with hypertension. Genetic Testing and Molecular Biomarkers 2015; 19: 124-7.
• 8. Balta S, Mikhailidis DP, Demirkol S, Ozturk C, Kurtoglu E, Demir M, Celik T, Turker T, Iyisoy A. Endocan--a novel inflammatory indicator in newly diagnosed patients with hypertension: a pilot study. Angiology 2014; 65: 773-7.
• 9. Liu N, Zhang LH, Du H, Hu Y, Zhang GG, Wang XH, Li JY, Ji JF. Overexpression of endothelial cell specific molecule-1 (ESM-1) in gastric cancer. Annals of Surgical Oncology 2010; 17: 2628-39.
• 10. Palmiere C, Augsburger M. Endocan measurement for the postmortem diagnosis of sepsis. Legal Medicine 2014; 16: 1-7.
• 11. Lee HG, Choi HY, Bae JS: Endocan as a potential diagnostic or prognostic biomarker for chronic kidney disease. Kidney International 2014; 86: 1079-81.
• 12. Yilmaz MI, Siriopol D, Saglam M et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney International 2014; 86: 1213-20.
• 13. Persson PB, Tepel M. Contrast medium-induced nephropathy: The pathophysiology. Kidney International Supplement 2006: 8-10.
• 14. Su YH, Shu KH, Hu CP, Cheng CH, Wu MJ, Yu TM, Chuang YW, Huang ST, Chen CH. Serum Endocan correlated with stage of chronic kidney disease and deterioration in renal transplant recipients. Transplantation Proceedings 2014; 46: 323-7.
• 15. Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal 2011; 32: 2999-3054.
• 16. Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. American Journal of Kidney Diseases : The Official Journal of The National Kidney Foundation 1998; 32: 853-906.
• 17. Thomsen HS. European Society of Urogenital Radiology (ESUR) guidelines on the safe use of iodinated contrast media. European Journal of Radiology 2006; 60: 307-13.
• 18. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Jama 2001; 285: 2486-97.
• 19. Toprak O, Cirit M. Risk factors for contrast-induced nephropathy. Kidney Blood Press Res 2006; 29: 84-93.
• 20. Pan HC, Wu XH, Wan QL, Liu, Bh, Wu XS. Analysis of the risk factors for contrast-induced nephropathy in over-aged patients receiving coronary intervention. Experimental Biology and Medicine 2018; 243: 970-5.
• 21. Parfrey P. The clinical epidemiology of contrast-induced nephropathy. Cardiovascular and Interventional Radiology 2005; 28: 3-11.
• 22. Gunay M, Mertoglu C. Increase of endocan, a new marker for inflammation and endothelial dysfunction, in acute kidney injury. Northern Clinics of Istanbul 2019; 6: 124-8.
• 23. Li S, Wang L, Wang C, Wang Q, Yang H, Liang P, Jin F. Detection on dynamic changes of endothelial cell specific molecule-1 in acute rejection after renal transplantation. Urology 2012; 80: 731-8.
• 24. Ando G, de Gregorio C, Morabito G, Trio O, Saporito F, Oreto G. Renal function-adjusted contrast volume redefines the baseline estimation of contrast-induced acute kidney injury risk in patients undergoing primary percutaneous coronary intervention. Circulation Cardiovascular Interventions 2014; 7: 465-72.
• 25. Abu El-Asrar AM, Nawaz MI, De Hertogh G, Al-Kharashi AS, Van den Eynde K, Mohammad G, Geboes K. The angiogenic biomarker endocan is upregulated in proliferative diabetic retinopathy and correlates with vascular endothelial growth factor. Current Eye Research 2015; 40: 321-31.